From the Journals

Pulmonary embolism common in patients with AE-COPD

View on the News

Use CTPA judiciously

“Early identification of these noninfectious events is important as standard antiexacerbation therapies including systemic corticosteroids and antibiotics are unlikely to be clinically useful for these etiologies and, importantly, may result in delays in the diagnosis and treatment of noninfectious causes of exacerbation such as acute coronary syndromes or congestive heart failure, leading to poor clinical outcomes.

“There is a clear and compelling need for more high quality evidence to determine the value of detecting PEs in patients with acute COPD exacerbations. There is an urgent need to understand the risks as well as the benefits of using CTPA [computed tomography pulmonary angiography] in the evaluation of acute COPD exacerbations. A Spanish group is currently conducting a randomized clinical trial to examine the clinical benefits and the safety of “routinely” deploying CTPA in the evaluation of hospitalized COPD patients with acute exacerbations (NCT02238639).

“What should clinicians do until high quality data from these and other studies are available? We suggest that in patients with typical infectious symptoms (e.g. increased cough, change in sputum volume or colour), CTPA is probably not required. CTPA may be considered for those who present with ‘atypical’ exacerbation symptoms (e.g. pleuritic chest pain, signs of cardiac failure, no clear identification of infectious origin) and in those with a prior history of thromboembolic disease. While we agree with Aleva and colleagues that the prevalence of PE is common (approximately 20%-25%) in unexplained COPD exacerbations, we remain unconvinced that all of these events require active treatment with anticoagulant therapy. Until compelling data from well-conducted randomized controlled trials are available, we suggest a conservative [first, no harm] approach to the management of acute exacerbations of COPD and [using] CTPA judiciously.”

Seung Won Ra, MD, PhD is with the Centre for Heart Lung Innovation, St. Paul’s Hospital and the department of medicine (respiratory division) at the University of British Columbia, Vancouver, as well as Ulsan (South Korea) University Hospital, University of Ulsan College of Medicine. Don D. Sin, MD, PhD is with the Centre for Heart Lung Innovation, St. Paul’s Hospital and the department of medicine (respiratory division) at the University of British Columbia, Vancouver. They had no relevant disclosures and made these remarks in an editorial (Chest. 2017;151[3]:523-4) that accompanied the published study.


 

FROM CHEST

About 16% of patients with unexplained chronic obstructive pulmonary disease (COPD) acute exacerbations (AE-COPD) had an accompanying pulmonary embolism (PE), usually in regions that could be targeted with anticoagulants, according to a new systematic review and meta-analysis.

About 70% of the time an AE is a response to infection, but about 30% of the time, an AE has no clear cause, the authors said in a report on their research (CHEST. 2017 March;151[3]:544-54). There is a known biological link between inflammation and coagulation, which suggests that patients experiencing AE-COPD may be at increased risk of PE.

The researchers reviewed and analyzed seven studies, comprising 880 patients. Among the authors’ reasons for conducting this research was to update the pooled prevalence of PE in AE-COPD from a previous systematic review published in CHEST in 2009.

The meta-analysis revealed that 16.1% of patients with AE-COPD were also diagnosed with PE (95% confidence interval 8.3%-25.8%). There was a wide range of variation between individual studies (prevalence 3.3%-29.1%). In six studies that reported on deep vein thrombosis, the pooled prevalence of DVT was 10.5% (95% CI 4.3%-19.0%).

Five of the studies identified the PE location. An analysis of those studies showed that 35.0% were in the main pulmonary artery, and 31.7% were in the lobar and inter-lobar arteries. Such findings “[suggest] that the majority of these embolisms have important clinical consequences,” the authors wrote.

The researchers also looked at clinical markers that accompanied AE-COPD and found a potential signal with respect to pleuritic chest pain. One study found a strong association between pleuritic chest pain and AE-COPD patients with PE (81.0% versus 40.0% in those without PE). A second study showed a similar association (24.0% in PE versus 11.5% in non-PE patients), and a third study found no significant difference.

The presence of PE was also linked to hypotension, syncope, and acute right failure on ultrasonography, suggesting that PE may be associated with heart failure.

Patients with PE were less likely to have symptoms consistent with a respiratory tract infection. They also tended to have higher mortality rates and longer hospitalization rates compared with those without PE.

The meta-analysis had some limitations, including the heterogeneity of findings in the included studies, as well as the potential for publication bias, since reports showing unusually low or high rates may be more likely to be published, the researchers noted. There was also a high proportion of male subjects in the included studies.

Overall, the researchers concluded that PE is more likely in patients with pleuritic chest pain and signs of heart failure, and less likely in patients with signs of a respiratory infection. That information “might add to the clinical decision-making in patients with an AE-COPD, because it would be undesirable to perform [computed tomography pulmonary angiography] in every patient with an AE-COPD,” the researchers wrote.

Next Article: